Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 4 Carcinoma, Basal Cell 4 Sarcoma, Kaposi 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Carcinoma 1

Interventions

pembrolizumab 8 Nivolumab 4 fludarabine 2 Cyclophosphamide 2 sonidegib 1 obinutuzumab 1 methyl 5-aminolevulinate 1 lutetium Lu 177 dotatate 1 fludarabine phosphate 1 durvalumab 1 daromun 1 cabozantinib 1 avelumab 1 atezolizumab 1 advexin 1 Tomography, Optical Coherence 1 Therapeutics 1 Taxes 1 Specimen Handling 1 Radiotherapy 1 ProMune 1 Pemetrexed 1 Paclitaxel 1 Oncolytic Virotherapy 1 Mesna 1 Magnetic Resonance Spectroscopy 1 MAPRE1 protein, human 1 Lutetium-177 1 Interleukin-2 1 HhAntag691 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma × daromun × Dermatologic × Clear all

NCT04362722 2023-10-10

DUNCAN

Philogen S.p.A.

Phase 2 Unknown

Carcinoma, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡